NEW YORK (GenomeWeb News) – NeoGenomics today reported third-quarter revenue growth of 26 percent year over year.

For the three months ended Sept. 30, the Ft. Meyers, Fla.-based cancer genetic testing firm said that revenues rose to $14.2 million from $11.3 million a year ago. The number of tests performed in the quarter increased to 28,315 from 19,977, but the average revenue per test dipped to $501.58 from $566.66.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.